Literature DB >> 6980254

Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2.

T J Eberlein, M Rosenstein, S A Rosenberg.   

Abstract

We have studied the ability of immunized lymphoid cells expanded in IL-2 to mediate the cure of mice with localized and disseminated syngeneic lymphoma. Mice received 500 rad total-body irradiation before injection of tumor into the footpad. Mice were treated 5 d later when a palpable local tumor and disseminated metastases were present. Intravenous injection of in vivo immune lymphocytes cured 93% of all mice, significantly better than any control group (P less than 0.0005). Immune cells, secondarily sensitized to the FBL-3 tumor in vitro, also conferred significant survival benefit (P less than 0.005) when injected intravenously, curing 79% of the animals treated. When these in vitro sensitized cells were expanded in IL-2, 8-10-fold over 7 d, 93% of the animals thus treated were cured, (P less than 0.005). When these cells were grown for multiple generations in IL-2 they retained their ability to cure mice (56% cured, P less than 0.01). This is the first demonstration that intravenous injection of sensitized cells grown in long term culture in IL-2 is capable of curing mice of established local and disseminated syngeneic tumor.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6980254      PMCID: PMC2186754          DOI: 10.1084/jem.156.2.385

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  21 in total

1.  Tumor neutralization, immunotherapy, and chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro: II. Comparison of cells cultured with and without tumor to noncultured immune cells.

Authors:  M A Cheever; P D Greenberg; A Fefer
Journal:  J Immunol       Date:  1978-12       Impact factor: 5.422

2.  Long term culture of tumour-specific cytotoxic T cells.

Authors:  S Gillis; K A Smith
Journal:  Nature       Date:  1977-07-14       Impact factor: 49.962

3.  In vitro growth of murine T cells. I. Production of factors necessary for T cell growth.

Authors:  S A Rosenberg; P J Spiess; S Schwarz
Journal:  J Immunol       Date:  1978-11       Impact factor: 5.422

4.  In vitro growth of murine T cells. II. Growth of in vitro sensitized cells cytotoxic for alloantigens.

Authors:  S A Rosenberg; S Schwarz; P J Spiess
Journal:  J Immunol       Date:  1978-11       Impact factor: 5.422

Review 5.  Passive immunotherapy of cancer in animals and man.

Authors:  S A Rosenberg; W D Terry
Journal:  Adv Cancer Res       Date:  1977       Impact factor: 6.242

6.  Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors.

Authors:  H Borberg; H F Oettgen; K Choudry; E J Beattie
Journal:  Int J Cancer       Date:  1972-11       Impact factor: 7.396

7.  Cross-resistance to the transplantation of syngeneic Friend, Moloney, and Rauscher virus-induced tumors.

Authors:  J P Glynn; J L McCoy; A Fefer
Journal:  Cancer Res       Date:  1968-03       Impact factor: 12.701

8.  T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor.

Authors:  M J Berendt; R J North
Journal:  J Exp Med       Date:  1980-01-01       Impact factor: 14.307

9.  Serologic identification of multiple tumor-associated antigens on murine sarcomas.

Authors:  G A Parker; S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1977-05       Impact factor: 13.506

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  64 in total

1.  The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein.

Authors:  T Matsutake; P K Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma.

Authors:  F P Holladay; T Heitz-Turner; W L Bayer; G W Wood
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

3.  Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: II. Characterization of cells cultured ex vivo and their contribution to the in vivo immunomodulation.

Authors:  C Fortis; E Ferrero; M Biffi; S Heltai; C Besana; E Bucci; M Tresoldi; C Rugarli
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity.

Authors:  Xiuli Zhang; Samuel Kim; Jasreet Hundal; John M Herndon; Shunqiang Li; Allegra A Petti; Savas D Soysal; Lijin Li; Mike D McLellan; Jeremy Hoog; Tina Primeau; Nancy Myers; Tammi L Vickery; Mark Sturmoski; Ian S Hagemann; Chris A Miller; Matthew J Ellis; Elaine R Mardis; Ted Hansen; Timothy P Fleming; S Peter Goedegebuure; William E Gillanders
Journal:  Cancer Immunol Res       Date:  2017-06-15       Impact factor: 11.151

Review 5.  Tumor-infiltrating lymphocytes in melanoma.

Authors:  Sylvia Lee; Kim Margolin
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

Review 6.  Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.

Authors:  Paul Mayor; Kristen Starbuck; Emese Zsiros
Journal:  Gynecol Oncol       Date:  2018-05-24       Impact factor: 5.482

Review 7.  Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?

Authors:  Christopher A Klebanoff; Luca Gattinoni; Nicholas P Restifo
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

8.  Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors:  Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  Science       Date:  2002-09-19       Impact factor: 47.728

Review 9.  Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.

Authors:  M H Geukes Foppen; M Donia; I M Svane; J B A G Haanen
Journal:  Mol Oncol       Date:  2015-10-30       Impact factor: 6.603

Review 10.  Progress and challenges in the vaccine-based treatment of head and neck cancers.

Authors:  Aldo Venuti
Journal:  J Exp Clin Cancer Res       Date:  2009-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.